Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510223 | 0.91 | GABRA1 (0.36) | GABRA1GABRB2MEN1KMT2APKM | |
| SCHEMBL3454178 | 0.76 | GABRA1 (0.42) | GABRA1GABRB2MEN1KMT2APKM | |
| SCHEMBL7836733 | 0.76 | GABRA1 (0.39) | GABRA1GABRB2MEN1KMT2APKM | |
| SCHEMBL239516 | 0.67 | SIRT2 (0.60) | KMT2ASMN1; SMN2ALDH1A1SIRT2NPSR1 | |
| Bicarbonate SCHEMBL28476605 | 0.67 | GABRA1 (0.39) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL26136210 | 0.67 | GRM2 (0.36) | GABRA1GABRB2MEN1KMT2APKM | |
| SCHEMBL27909384 | 0.66 | HDAC3 (0.32) | SIRT2NPSR1TSHRRXFP1HDAC3 | |
| SCHEMBL3205167 | 0.66 | PLA2G2A (0.32) | MEN1KMT2AMAPTKDM4E | |
| SCHEMBL3658175 | 0.63 | CNR2 (0.40) | GABRA1GABRB2MAPTLMNAKDM4E | |
| SCHEMBL28134450 | 0.62 | GABRA1 (0.43) | GABRA1GABRB2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104231008-B | The Regioselective synthesis of nucleoside medicine 5 ' bit amino acid esters | 沈阳药科大学 | 2017-03-01 | — | — | CN | disclosed |
| CN-104231008-A | Regional selective synthesis method of nucleoside drug 5'-site amino-acid ester | UNIV SHENYANG PHARMACEUTICAL | 2014-12-24 | — | — | CN | disclosed |
| US-8012430-B2 | Methods for producing microchannel chips, microchannel chips, methods for separating biomolecules using the microchannel chips, and electrophoretic apparatus having the microchannel chips | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100101953-A1 | Methods for producing microchannel chips, microchannel chips, methods for separating biomolecules using the microchannel chips, and electrophoretic apparatus having the microchannel chips | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20060113189-A1 | Method for separating substances | KARUBE, ISAO (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1548429-A1 | METHOD FOR SEPARATING SUBSTANCES | Katayanagi Institute (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6803198-B2 | COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6322987-B1 | FOR TREATING AN ANIMAL HAVING A DISEASE CHARACTERIZED BY UNDESIRED PRODUCTION OF PROTEIN | ISIS PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0983291-A4 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6166188-A | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6111085-A | COMPOUND HAVING AT LEAST ONE NUCLEOSIDE WITH A DERIVATIVE AT THE 2'-O OR 3'-O POSITION; FOR IMPROVED PROPERTIES AND CONJUGATION OF FUNCTIONAL MOIETIES SUCH AS STEROIDS, REPORTER MOLECULES, REPORTER ENZYMES, LIPOPHILIC MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0983291-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998011123-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | GABRA1 4031/4885GABRB2 3669/4885MEN1 2452/4885 |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | GABRA1 4031/4885GABRB2 3669/4885MEN1 2452/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | GABRA1 1579/4885GABRB2 2319/4885MEN1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.